Vivitrol News and Research

RSS
Vivitrol is a drug that blocks the action of opiates (drugs used to treat pain). It may be used in the treatment of intravenous opiate addiction or alcohol dependence. Vivitrol is also being studied in the treatment of breast cancer. It may block the effects of the hormone estrogen, which causes some breast cancer cells to grow, or block the blood flow to tumors. It is a type of opiate antagonist. Also called naltrexone, naltrexone hydrochloride, and ReVia.
Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

PMAI offers new addiction treatment options for opioid dependence

PMAI offers new addiction treatment options for opioid dependence

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes' VIVITROL medication for treatment of opioid dependence

FDA approves Vivitrol for treatment of opioid-dependent patients

FDA approves Vivitrol for treatment of opioid-dependent patients

Alcohol addiction drug may help opioid addicts: FDA panel considers reports

Alcohol addiction drug may help opioid addicts: FDA panel considers reports

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Positive results from Alkermes' ALKS 33 clinical trials announced

Positive results from Alkermes' ALKS 33 clinical trials announced

Alcohol-dependence study looks at impact of pharmacotherapy on quality-of-life

Alcohol-dependence study looks at impact of pharmacotherapy on quality-of-life